Pomerantz Law Firm Issues Litigation Deadlines for TCOM, AQST, and DRVN

Pomerantz Law Firm, a preeminent force in securities litigation, has intensified its focus on three distinct corporate entities: Trip.com Group Limited, Aquestive Therapeutics, Inc., and Driven Brands Holdings Inc. These alerts, issued simultaneously on March 13, 2026, serve as a critical juncture for institutional and retail investors who suffered financial losses during specified class periods. By setting firm deadlines for lead plaintiff applications, the firm is signaling a robust push to hold these companies accountable for alleged failures in transparency and material disclosure. This wave of litigation underscores a broader trend in the 2026 market environment, where regulatory scrutiny and shareholder activism are increasingly converging to challenge corporate narratives.

Trip.com Group Limited (TCOM), a global leader in the travel services sector, finds itself under the legal microscope during a period of complex geopolitical and economic shifts. As a company with significant operations in China and a growing international footprint, Trip.com is particularly vulnerable to disclosures regarding regulatory compliance and market expansion risks. Securities class actions in the travel tech space often hinge on the accuracy of growth projections and the impact of regional regulatory changes on bottom-line performance. For TCOM, the litigation represents a potential headwind as it navigates the post-pandemic recovery of the global tourism industry, where investor confidence is paramount.

“

Pomerantz Law Firm, a preeminent force in securities litigation, has intensified its focus on three distinct corporate entities: Trip.com Group Limited, Aquestive Therapeutics, Inc., and Driven Brands Holdings Inc.

In the pharmaceutical and biotechnology sector, Aquestive Therapeutics, Inc. (AQST) faces allegations that are characteristic of the high-stakes drug development landscape. Historically, litigation against biotech firms often centers on the communication of clinical trial results or the status of FDA approval processes. For Aquestive, which specializes in innovative delivery systems for complex molecules, any perceived lack of transparency regarding its pipeline or regulatory interactions can lead to sharp declines in market capitalization. This case serves as a reminder to life sciences executives that the 'duty to disclose' is not merely a legal formality but a fundamental component of market stability, especially when dealing with speculative drug candidates.

Driven Brands Holdings Inc. (DRVN), the largest automotive services company in North America, represents a different facet of the litigation wave. Operating brands like Take 5 Oil Change and Meineke, the company has pursued an aggressive growth-through-acquisition strategy. Class action lawsuits in this sector frequently target the integration of these acquisitions and the realization of promised synergies. If a company fails to meet its stated growth targets or encounters unforeseen operational hurdles during brand consolidation, shareholders often seek recourse through the courts. The Pomerantz alert for DRVN highlights the risks inherent in rapid corporate scaling and the necessity of maintaining rigorous internal controls to ensure accurate financial reporting.